Opus Genetics (IRD) Other financing activities (2011 - 2026)
Opus Genetics (IRD) posted quarterly Other financing activities of $738000.0 for Q1 2026, up 14660.0% year-over-year from N/an in Q1 2025, and down 6.94% quarter-over-quarter from $793000.0 in Q4 2025.
Opus Genetics (IRD) Other financing activities (2011 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Other financing activities for 11 consecutive years, with $738000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 14660.0% year-over-year to $738000.0; the TTM figure through Mar 2026 stood at $1.6 million (up 30960.0% YoY), while the FY2025 annual figure was $820000.0, changed N/A from the prior year.
- Other financing activities fell to $738000.0 in Q1 2026 per IRD's latest filing, from $793000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $793000.0 in Q4 2025 and bottomed at $5000.0 in Q1 2025.
- Historically, Other financing activities has averaged $269166.7 across 4 years, with a median of $28500.0 in 2022.
- Annual changes were most pronounced in 2022 — Other financing activities jumped 170.0% — and 2026, when it soared 14660.0%.
- Opus Genetics' Other financing activities stood at $27000.0 in 2022, then rose by 11.11% to $30000.0 in 2023, then surged by 2543.33% to $793000.0 in 2025, then retreated by 6.94% to $738000.0 in 2026.
- Business Quant data shows IRD's Other financing activities at $738000.0 in Q1 2026, $793000.0 in Q4 2025, and $22000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 925,000.00 |
| Jun 30, 2026 | 925,000.00 |
| Mar 31, 2026 | 738,000.00 |
| Mar 31, 2026 | 738,000.00 |
| Dec 31, 2025 | 793,000.00 |
| Dec 31, 2025 | 793,000.00 |
| Sep 30, 2025 | 22,000.00 |
| Sep 30, 2025 | 22,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2023 | 30,000.00 |
| Dec 31, 2023 | 30,000.00 |
| Mar 31, 2022 | 27,000.00 |
| Mar 31, 2022 | 27,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Sep 30, 2021 | 76,000.00 |
| Sep 30, 2021 | 76,000.00 |
| Mar 31, 2021 | 10,000.00 |
| Mar 31, 2021 | 10,000.00 |